{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "CitationSubset": ["IM"], "OtherAbstract": [], "KeywordList": [["Cuba", "IgA deficiency", "Ozone therapy", "antioxidants", "oxidative stress", "primary immunodeficiency", "pro-oxidants"]], "GeneralNote": [], "OtherID": [], "InvestigatorList": [], "PMID": "34229419", "DateRevised": {"Year": "2021", "Month": "07", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "02", "Day": "10"}], "Language": ["eng"], "ELocationID": ["10.37757/MR2018.V20.N1.7"], "Journal": {"ISSN": "1527-3172", "JournalIssue": {"Volume": "20", "Issue": "1", "PubDate": {"Year": "2018", "Month": "Jan"}}, "Title": "MEDICC review", "ISOAbbreviation": "MEDICC Rev"}, "ArticleTitle": "Systemic Ozone Therapy by Rectal Insufflation for Immunoglobulin A Deficiency.", "Pagination": {"StartPage": "29", "MedlinePgn": "29"}, "Abstract": {"AbstractText": ["IgA deficiency is a primary immunodeficiency predominantly due to an antibody defect, for which there is no replacement therapy. Treatment consists of prevention and treatment of infections and other associated conditions. Given the immunomodulatory and regulatory properties of the redox balance of ozone therapy in infectious and inflammatory conditions, evaluation of its effect on IgA deficiency is of interest.", "Assess the benefits and possible adverse effects of ozone treatment in patients with IgA deficiency.", "A monocentric randomized controlled phase 2 clinical trial (RPCEC 00000236) was carried out, after approval by the Institutional Ethics Committee of the Roberto Rodr\u00edguez Fern\u00e1ndez Provincial General Teaching Hospital in Mor\u00f3n, Ciego de \u00c1vila Province, Cuba. Included were 40 patients aged 5-50 years, distributed in 2 groups of 20, after agreeing to participate and signing informed consent. The experimental group received 2 cycles of ozone by rectal insufflation for 20 days (5 times a week for 4 weeks each cycle) with a 3-month interval between cycles, for a total of 40 doses, with age-adjusted dose ranges. The control group was treated with leukocyte transfer factor (Hebertrans), 1 U per m<sup>2</sup> of body surface area subcutaneously, once weekly for 12 weeks. Frequency of appearance and severity of clinical symptoms and signs of associated diseases, serum immunoglobulin concentrations and balance of pro-oxidant and antioxidant biomarkers were recorded at treatment initiation and one month after treatment completion. Therapeutic response was defined as complete, partial, stable disease or progressive disease. Descriptive statistics and significance were calculated to compare groups and assess effect size.", "One month after treatment completion, 70% of patients in the experimental group experienced significant increases in IgG(p = 0.000) and IgM (p = 0.033). The experimental group also displayed decreased pro-oxidation biomarkers, glutathione modulation and increased antioxidant enzymes, with reduced oxidative stress; none of these occurred in the control group. Complete therapeutic response was achieved in 85% of patients in the experimental group and only 45% in the control group. Mild, transient adverse events were reported in both groups.", "Ozone therapy by rectal insufflation is a suitable therapeutic option for treating IgA deficiency because it produces antioxidant and immunomodulatory effects and is feasible, safe and minimally invasive.", "This paper introduces in Cuba a new treatment a for IgA deficiency, with immunomodulatory and antioxidant effects offering substantial clinical benefits to patients with this immunodeficiency."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Roberto Rodr\u00edguez Fern\u00e1ndez Provincial General Teaching Hospital, Mor\u00f3n, Cuba."}], "Identifier": [], "LastName": "D\u00edaz-Luis", "ForeName": "Jacqueline", "Initials": "J"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "National Scientific Research Center, Havana, Cuba."}], "Identifier": [], "LastName": "Men\u00e9ndez-Cepero", "ForeName": "Silvia", "Initials": "S"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Hematology and Immunology Institute, Havana, Cuba."}], "Identifier": [], "LastName": "Mac\u00edas-Abraham", "ForeName": "Consuelo", "Initials": "C"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "National Medical Genetics Center, Havana, Cuba."}], "Identifier": [], "LastName": "Fari\u00f1as-Rodr\u00edguez", "ForeName": "Luc\u00eda", "Initials": "L"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "MEDICC Rev", "NlmUniqueID": "100964771", "ISSNLinking": "1527-3172"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Raje N, Dinakar C. Overview of immunodeficiency disorders. Immunol Allergy Clin North Am [Internet]. 2015 Nov [cited 2017 Feb 21];35(4):599\u2013623. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600970/"}, {"Citation": "Mac\u00edas C, S\u00e1nchez M, Insua C, Garc\u00eda MC, Hern\u00e1ndez G, Arce A, et al. Tratamiento con inmunoglobulina G subcut\u00e1nea en enfermos con inmunodeficiencias primarias: resultados preliminares del estudio multic\u00e9ntrico cubano. Rev Cubana Hematol Inmunol Hemoterapia [Internet]. 2016 [cited 2017 Feb 20];32(3):1\u201310. Available from: http://revhematologia.sld.cu/index.php/hih/article/view/449/251. Spanish."}, {"Citation": "Kobrynski L, Waltenburg Powell R, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001\u20132007. J Clin Immunol [Internet]. 2014 [cited 2016 Mar 3];34(8):954\u201361. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820073/"}, {"Citation": "European Society for Immunodeficiencies [Internet]. Geneva: European Society for Immunodeficiencies; c2017. Registry. Diagnosis Criteria. New clinical diagnosis criteria for the ESID Registry; 2014 Mar [cited 2017 Feb 21]; [about 1 screen]. Available from: http://esid.org/Working-Parties/Registry/Diagnosis-criteria"}, {"Citation": "\u00d6zcan C, Metin A, Erko\u00e7oglu M, Kocabas CN. Bronchial hyperreactivity in children with antibody deficiencies. Allergol Immunopathol (Madr). 2015 Jan\u2013Feb;43(1):57\u201361."}, {"Citation": "Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. Autoimmun Rev [Internet]. 2014 Feb [cited 2017 Jan 20];13(2):163\u201377. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1568-9972(13)00180-8"}, {"Citation": "Grupo de Trabajo de Inmunolog\u00eda Pedi\u00e1trica. Gu\u00edas de manejo: medidas generales de prevenci\u00f3n de infecciones y quimioprofilaxis en las inmunodeficiencias primarias. Arch Argent Pediatr [Internet]. 2011 [cited 2016 Mar 3];109(3):267\u201373. Available from: http://www.scielo.org.ar/pdf/aap/v109n3/v109n3a19.pdf. Spanish."}, {"Citation": "Garc\u00eda Mart\u00ednez JM, Santos-D\u00edez L, Dopazo L. Diagn\u00f3stico de las inmunodeficiencias primarias. Protoc Diagn Ter Pediatr [Internet]. 2013 [cited 2016 Feb 24];1:81\u201392. Available from: http://www.aeped.es/sites/default/files/documentos/7-inmunodeficiencias_primarias_0.pdf. Spanish."}, {"Citation": "Abbas AK, Lichtman AH, Pillai S. Propiedades generales de las respuestas inmunitarias. In: Abbas AK, Lichtman AH, editors. Inmunolog\u00eda celular y molecular. 8th ed [Internet]. Barcelona: Elsevier; 2015 [cited 2017 Feb 21]. Available from: http://booksmedicos.me/inmunologia-celular-y-molecular-abbas-8a-edicion/. Spanish."}, {"Citation": "Bocci V. Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses [Internet]. 1996 Feb [cited 2017 Feb 21];46(2). Available from: http://www.ncbi.nlm.nih.gov/pubmed/8692040"}, {"Citation": "Mart\u00ednez-S\u00e1nchez G. La ozonoterapia gana evidencia cient\u00edfica en el campo cl\u00ednico. Rev Cubana Farm [Internet]. 2013 Apr 9 [cited 2016 Feb 24];47(1):1\u20134. Available from: http://bvs.sld.cu/revistas/far/vol47_1_13/far01113.htm. Spanish."}, {"Citation": "Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicol In Vitro [Internet]. 2005 Feb [cited 2016 Mar 3];19(1):55\u201361. Available from: http://www.ozonoterapiafrancia.com.mx/_downloads/Publicaciones_Ozono/Bocci%202.pdf"}, {"Citation": "Nazarina I, Men\u00e9ndez S, Rivero J. Ozonoterapia en SIDA. Rev Cubana Invest Biomed [Internet]. 2005 Jan\u2013Mar [cited 2017 Feb 21];24(1):69\u201371. Available from: http://bvs.sld.cu/revistas/ibi/vol24_1_05/ibi09105.pdf. Spanish."}, {"Citation": "Le\u00f3n Fern\u00e1ndez OS, Viebahn-Haensler R, Cabreja GL, Espinosa IS, Matos YH, Roche LD, et al. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Eur J Pharmacol [Internet]. 2016 Oct 15 [cited 2017 Feb 21];789:313\u20138. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(16)30471-X"}, {"Citation": "D\u00edaz Luis J, Padr\u00f3n Sardi\u00f1as G, Men\u00e9ndez Cepero S, Mac\u00edas Abraham C. [Immunomodulator effect of ozone therapy in children with deficiency in immunity mediated by phagocytes]. Mediciego [Internet]. 2012 [cited 2016 Jan 4];18(1). Available from: http://bvs.sld.cu/revistas/mciego/vol18_01_2012/pdf/T9.pdf. Spanish."}, {"Citation": "Gazin IK, Istomin N. [Disturbed immune status and immunocorrective effect of ozone-assisted therapy in comparison with traditional treatment of patients with diabetes mellitus complicated by pyonecrotic lesions of the lower extremities]. Immunologiya. 2009;(1):60\u20131. Russian."}, {"Citation": "Asociaci\u00f3n Espa\u00f1ola de Profesionales M\u00e9dicos en Ozonoterapia (AEPROMO). Declaraci\u00f3n de Madrid sobre ozonoterapia [Internet]. Madrid: AEPROMO; 2012 [cited 2014 Nov 20]. Available from: http://files.sld.cu/rehabilitacion-fis/files/2012/06/declaracion-de-madrid-actualizada-30-julio-castellano-20102.pdf. Spanish."}, {"Citation": "Viebahn-H\u00e4nsler R, Le\u00f3n Fern\u00e1ndez OS, Fahmy Z. Ozone in medicine: the low-dose ozone concept guidelines and treatment strategies. Ozone Sci Engineering. 2012;34(6):408\u201324."}, {"Citation": "Formulario Nacional de Medicamentos. Factor de Transferencia [Internet]. Havana: Centro para el Desarrollo de la Farmacoepidemiolog\u00eda (CU); 2017 [cited 2017 Dec 12]; [about 2 screens]. Available from: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=380. Spanish."}, {"Citation": "Ruiz Contreras J, Gonz\u00e1lez Granado LI. Pruebas de laboratorio en el diagn\u00f3stico de inmunodeficiencias primarias. An Pediatr Cont [Internet]. 2013 [cited 2016 Feb 24];11(5):282\u201390. Available from: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S1696281813701495. Spanish."}, {"Citation": "Rozman C, Cardellach L\u00f3pez F. Farreras Rozsman. Medicina Interna [Internet]. Barcelona: Elsevier; c2016 [cited 2017 Feb 21]. Chapter 338, Pruebas inmunol\u00f3gicas de inter\u00e9s diagn\u00f3stico; p. 2534\u201349. Available from: https://www.clinicalkey.es/#!/content/book/3-s2.0-B9788480868969003381. Spanish."}, {"Citation": "BIOPROCESS Online [Internet]. Pittsburg: BIOPREOCESS Online; c1996\u20132017. Product/Service. Bioxytech LPO-586. Colorimetric assay for lipid peroxidation markers. Catalogue No. 941012. OXIS International, 1997; [cited 2016 Mar 3]; [about 1 screen]. Available from: https://www.bioprocessonline.com/doc/bioxytech-lpo-586-colorimetric-assay-for-lipi-0001"}, {"Citation": "Witko-Sarsat V, Friendlander M, Nguyen-Khoa T, Capeill\u00e8re-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocytes activation in chronic renal failure. J Immunol. 1998 Sep 1;161(5):2524\u201332."}, {"Citation": "Jiang ZY, Woollard AC, Wolff SP. Lipid hydroperoxide measurement by oxidation of Fe2+ in the presence of xylenol orange. Comparison with the TBA assay and an iodometric method. Lipids. 1991 Oct;26(10):853\u20136."}, {"Citation": "Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974 Sep 16;47(3):469\u201374."}, {"Citation": "Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121\u20136."}, {"Citation": "Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967 Jul;70(1):158\u201369."}, {"Citation": "Sedlak J, Lindasy RH. Estimation of total protein bound and non-protein sulfhydryl group in tissue with Ellman\u2019s reagent. Anal Biochem. 1968 Oct 24;25(1):192\u2013205."}, {"Citation": "Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem. 1996 Jul 15;239(1):70\u20136."}, {"Citation": "Ministry of Public Health (CU); Center for State Control of Medicines, Equipment and Medical Devices (CU). Regulaci\u00f3n No. 45-2007. Requerimientos para la notificaci\u00f3n y el reporte de eventos adversos graves e inesperados en los ensayos cl\u00ednicos 2007 [Internet]. Havana: National Quality Control Center for Drugs, Medical Equipment and Devices (CU); 2007 [cited 2011 Jan]. 18 p. Available from: http://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/reg_45-07_requerimientos_para_la_notificacion_y_el_reporte_de_eventos_adversos_graves_e_inesperados_en_los_ensayos_clinicos.pdf. Spanish."}, {"Citation": "World Medical Association. Declaraci\u00f3n de Helsinki de la Asociaci\u00f3n M\u00e9dica Mundial. Principios \u00e9ticos para las investigaciones m\u00e9dicas en seres humanos. Junio 1964 [Internet]. Ferney-Voltaire: World Medical Association; 2017 Mar 21 [cited 2011 Jan 10]; [about 5 screens]. Available from: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/. Spanish."}, {"Citation": "Dom\u00ednguez O, Giner MT, Alsina L, Mart\u00edn MA, Lozano J, Plaza AM. Fenotipos cl\u00ednicos asociados a la deficiencia selectiva de IgA: revisi\u00f3n de 330 casos y propuesta de un protocolo de seguimiento. An Pediatr [Internet]. 2012 [cited 2016 Feb 24];76(5):261\u20137. Available from: http://www.analesdepediatria.org/es/fenotipos-clinicos-asociados-deficiencia-selectiva/articulo/S1695403311005522/. Spanish."}, {"Citation": "De Oliveira-Serra FA, Mosca T, Santos de Menezes MC, Carvalho-Neves Forte W. Manifestaciones cl\u00ednicas de la deficiencia de IgA. Rev Alerg Mex [Internet]. 2017 [cited 2017 Feb 24];64(1):34\u20139. Available from: http://revistaalergia.mx/ojs/index.php/ram/article/view/216/436. Spanish."}, {"Citation": "Urm SH, Yun HD, Fenta YA, Yoo KH, Abraham RS, Hagan J, et al. Asthma and risk of celective IgA deficiency or common variable immunodeficiency: a population-based case-control study. Mayo Clin Proc [Internet]. 2013 Aug [cited 2016 Jun 20];88(8):813\u201321. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23910409/"}, {"Citation": "Rivas JJ, Brocardo GA, Kokron C, Rizzo LV, Kalil J, Barros MT. Caracteriza\u00e7\u00e3o imunofenot\u00edpica de linf\u00f3citos B de mem\u00f3ria na defici\u00eancia de IgA e imunodefici\u00eancia comum vari\u00e1vel. Rev Bras Alergia Imunopatol [Internet]. 2010 Jan\u2013Feb [cited 2016 Jun 20];33(1):23\u201331. Available from: http://pesquisa.bvsalud.org/bvsecuador/resource/pt/lil-563501. Portuguese."}, {"Citation": "Soheili H, Abolhassani H, Arandi N, Khazaei HA, Shahinpour S, Hirbod\u2013Mobarakeh A, et al. Evaluation of natural regulatory T cells in subjects with selective IgA deficiency: from senior idea to novel opportunities. Int Arch Allergy Immunol. 2013;160(2):208\u201314."}, {"Citation": "Bezrodnik L, Di Giovanni D, Ginaca A, Krasovec S, Menard D, Carabajal P, et al. Evaluaci\u00f3n cl\u00ednica e inmunol\u00f3gica de 90 pacientes con deficiencia selectiva de inmunoglobulina A. Arch Argent Pediatr [Internet]. 2003 Sep\u2013Oct [cited 2016 Mar 3];101(5):375\u201381. Available from: http://www.imbiomed.com/1/1/articulos.php?method=showDetail&id_articulo=44150&id_seccion=2737&id_ejemplar=4481&id_revista=165. Spanish."}, {"Citation": "Cruz Barrios MA, Rodr\u00edguez Montiel BN, Furones Mourelle JA, Mart\u00edn de la Riva AD, Guerra Su\u00e1rez LM, P\u00e1ez P\u00e9rez AT. Patrones de prescripci\u00f3n del factor de transferencia en 11 hospitales de Ciudad de La Habana. Rev Cubana Salud P\u00fablica [Internet]. 2005 Dec [cited 2016 Mar 3];31(4):291\u20135. Available from: http://www.redalyc.org/articulo.oa?id=21418845004&idp=1&cid=34574. Spanish."}, {"Citation": "Incl\u00e1n G. Respuesta cl\u00ednica e inmunol\u00f3gica en pacientes con d\u00e9ficit de IgA despu\u00e9s del tratamiento con factor de transferencia. Rev Cub Hematol Inmunol Hemoterapia. 1994;10:80\u20131. Spanish."}, {"Citation": "Mart\u00ednez S\u00e1nchez G, Re L. Rectal administration and its application in ozone therapy. Intl J Ozone Therapy. 2012 Apr;11:41\u20139."}, {"Citation": "Mandzhgaladze NR, Kharebava ER, Didia TsG, Ardzhevanishvili MD, Gudzhabidze MV, Chigiashvili TsN. [Influence of intravenous ozone treatment on the level of different specificity antibodies]. Georgian Med News [Internet]. 2006 Sep [cited 2017 Feb 21];(138):93\u20135. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17057311"}, {"Citation": "D\u00edaz Luis J, Mac\u00edas Abraham C, Men\u00e9ndez Cepero S. Efecto modulador de la ozonoterapia sobre la actividad del sistema inmune. Rev Cubana Hematol Inmunol Hemoterapia [Internet]. 2013 [cited 2017 Feb 21];29(2). Available from: http://www.revhematologia.sld.cu/index.php/hih/article/view/27. Spanish."}, {"Citation": "Smith AJ, Oertle J, Warren D, Prato D. Ozone Therapy: a critical physiological and diverse clinical evaluation with regard to immune modulation, anti-infectious properties, anti-cancer potential, and impact on anti-oxidant enzymes. Open J Molecular Integr Physiol. 2015 Aug;5(3):37\u201348."}, {"Citation": "S\u00e1nchez Valle V, M\u00e9ndez S\u00e1nchez N. Estr\u00e9s oxidativo, antioxidantes y enfermedad. Rev Invest Med Sur Mex [Internet]. 2013 Jul\u2013Sep [cited 2016 Jul 24];20(3):161\u20138. Available from: http://medicasur.org.mx/pdf-revista/RMS133-AR01-PROTEGIDO.pdf. Spanish."}, {"Citation": "Elejalde Guerra JI. Estr\u00e9s oxidativo, enfermedades y tratamientos antioxidantes. An Med Interna [Internet]. 2001 Jun [cited 2017 Jan 5];18(6):326\u201335. Available from: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992001000600010. Spanish."}, {"Citation": "Pomier Su\u00e1rez O, Gil del Valle L, Rodr\u00edguez Delgado F, Huetes L, Alerm Gonz\u00e1lez A, Berm\u00fadez Alfonso Y, et al. Indicadores de estr\u00e9s oxidativo en pacientes afectados por VIH/sida con manifestaciones reumatol\u00f3gicas. Rev Cubana Farm. 2012 Jul\u2013Sep;46(3):329\u201342. Spanish."}, {"Citation": "Hern\u00e1ndez Rosales FA, Calunga Fern\u00e1ndez JL, Turrent Figueras J, Men\u00e9ndez Cepero S, Montenegro Perdomo A. Ozone therapy effects on biomarkers and lung function in asthma. Arch Med Res. 2005 Sep\u2013Oct;36(5):549\u201354."}, {"Citation": "Corcho I, Hern\u00e1ndez F, Reyes N, Carballo AL, Pe\u00f1a O, Reyes T, et al. [Changes in the immune system in inflammatory processes during the application of ozone therapy]. Rev CENIC Cienc Biol [Internet]. 1998 [cited 2017 Feb 21];29(3):203\u20135. Available from: http://amozon.org.mx/index.php/blog/63-alergia-e-inmunologia/1171-changes-in-the-immune-system-in-inflammatory-processes-during-the-application-of-ozone-therapy. Spanish."}, {"Citation": "Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem [Internet]. 2015 Feb 2 [cited 2016 Mar 3];3:4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25699252/"}, {"Citation": "Copello M, Men\u00e9ndez S, Hern\u00e1ndez F. Ozone therapy in retinitis pigmentosa patients: clinical evolution and oxidative stress behavior in retinitis pigmentosa patients treated with ozone therapy over 20 years. Ozone Sci Engineering. 2012 Dec 5;34(6):476\u201383."}, {"Citation": "Cruz Barrios MA. Reacciones adversas del factor de transferencia y caracter\u00edsticas de su prescripci\u00f3n. La Habana, 2001\u20132010 [thesis] [Internet]. [Havana]: Dr Miguel Enr\u00edquez Medical School; 2014 [cited 2017 Feb 21]. Available from: http://tesis.repo.sld.cu/863/1/Cruz_Barrios.pdf. Spanish."}]}], "History": [{"Year": "2017", "Month": "8", "Day": "21"}, {"Year": "2017", "Month": "12", "Day": "18"}, {"Year": "2021", "Month": "7", "Day": "7", "Hour": "1", "Minute": "3"}, {"Year": "2018", "Month": "1", "Day": "1", "Hour": "0", "Minute": "0"}, {"Year": "2018", "Month": "1", "Day": "1", "Hour": "0", "Minute": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34229419", "10.37757/MR2018.V20.N1.7"]}}]}